Document Detail


Genetic variants in haem oxygenase-1 and endothelial nitric oxide synthase influence the extent and evolution of coronary artery atherosclerosis.
MedLine Citation:
PMID:  22123460     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The genetic basis for atherosclerosis development and progression is poorly characterized. We aimed to assess the relationship between endothelial nitric oxide synthase (ENOS) 894 G/T, haem oxygenase-1 (HO1) dinucleotide-length promoter polymorphisms and coronary artery atherosclerotic invol vement and its changes during statin therapy. Coronary angiography, intravascular ultrasound (IVUS), IVUS-derived virtual histology (VH) and genetic polymorphism analysis were performed at study entry. Patients were randomized 1:1 to standard or aggressive hypolipidaemic treatment, and a follow-up evaluation was performed after twelve months. Plaque magnitude was significantly higher in carriers of HO1 risk variants when compared with carriers of the protective variants (< 25 GT repeats). Similarly, the total coronary atherosclerotic burden was significantly greater in HO1 risk variant carriers than in HO1 protective variant carriers. Both parameters did not differ with respect to the ENOS genotype. A higher prevalence of thin-cap fibroatheroma (TCFA) in HO1 risk variant carriers was observed, compared with the HO1 protective variant carriers. The prevalence of TCFA was not influenced by the ENOS genotype. Baseline plaque composition did not differ significantly with respect to both polymorphisms. Significant interactions between plaque composition changes and ENOS and HO1 genotypes were observed during statin treatment. In conclusion, the protective HO1 promoter polymorphism correlates with a lower coronary artery plaque burden, whereas the protective ENOS 894 G/T polymorphism seems to favourably influence changes of coronary artery plaque composition during statin therapy, but has no significant correlation to the magnitude of coronary atherosclerosis.
Authors:
A Král; T Kovárník; L Králík; H Skalická; J Horák; G S Mintz; J Uhrová; M Sonka; A Wahle; R Downe; M Aschermann; P Martásek; A Linhart
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Folia biologica     Volume:  57     ISSN:  0015-5500     ISO Abbreviation:  Folia Biol. (Praha)     Publication Date:  2011  
Date Detail:
Created Date:  2011-11-29     Completed Date:  2012-06-05     Revised Date:  2012-08-22    
Medline Journal Info:
Nlm Unique ID:  0234640     Medline TA:  Folia Biol (Praha)     Country:  Czech Republic    
Other Details:
Languages:  eng     Pagination:  182-90     Citation Subset:  IM    
Affiliation:
Second Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic. ales.kral@vfn.cz
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Coronary Angiography
Coronary Artery Disease / diagnosis,  drug therapy,  enzymology*,  genetics
Coronary Vessels / pathology*,  ultrasonography
Endothelial Cells / enzymology*
Female
Genetic Variation*
Genotype
Heme Oxygenase-1 / genetics*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Male
Middle Aged
Nitric Oxide Synthase Type III / genetics*
Polymorphism, Genetic
Ultrasonography, Interventional
Chemical
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; EC 1.14.13.39/Nitric Oxide Synthase Type III; EC 1.14.99.3/Heme Oxygenase-1

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Chromogranin a in physiology and oncology.
Next Document:  Study of the effect of neoadjuvant chemotherapy on the status of Her2/neu.